Larimar Therapeutics prices $64.4M common stock offering at $3.20 per share

Larimar Therapeutics, Inc.

Offering of 18,750,000 shares of common stock at $3.20; underwriters' over-allotment of 2,812,500 shares exercised in full.
Net proceeds expected approximately $64.4 million after underwriting discounts and expenses.
Joint book-running managers: Leerink Partners, Guggenheim Securities, Truist Securities, William Blair.
Offering expected to close July 31, 2025, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.